about
Oral antineoplastic agents: how do we care about adherence?Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: Methodology of clinical trials and clinical benefit.Cognitive complaints in cancer: The French version of the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog), normative data from a healthy population.Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial.Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.Evaluation of the impact of the cancer therapy everolimus on the central nervous system in miceStandard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer.Predictive factors of 18F-choline PET/CT positivity in patients with prostate cancer recurrence after radiation therapy: is the impact of PSA nadir underestimated?Cross-cultural adaptation and validation of the French version of the Expanded Prostate cancer Index Composite questionnaire for health-related quality of life in prostate cancer patients.Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B StudyBiomarkers Associated with Cognitive Impairment in Treated Cancer Patients: Potential Predisposition and Risk Factors.Autobiographical memory, self, and stress-related psychiatric disorders: which implications in cancer patients?Cognitive dysfunctions in elderly cancer patients: a new challenge for oncologists.Quality of life research in endometrial cancer: what is needed to advance progress in this disease site? Methodological considerations from the Gynecologic Cancer InterGroup Symptom Benefit Working Group brainstorming session, Leiden 2012.Role of physical activity and sport in oncology: scientific commission of the National Federation Sport and Cancer CAMI.Impact of Cancer and Its Treatments on Cognitive Function: Advances in Research From the Paris International Cognition and Cancer Task Force Symposium and Update Since 2012.Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer.Ovarian cancer survivors' quality of life: a systematic review.Statistical controversies in clinical research: should schedules of tumor size assessments be changed?A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.Decline in Cognitive Function in Older Adults With Early-Stage Breast Cancer After Adjuvant Treatment.Pharmacokinetic interaction between pazopanib and cisplatin regimen.Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial.Impact of new generation hormone-therapy on cognitive function in elderly patients treated for a metastatic prostate cancer: Cog-Pro trial protocol.Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies.A phase II trial evaluating the efficacy and safety of efavirenz in metastatic castration-resistant prostate cancerQuality of life and patient-reported outcomes in endometrial cancer clinical trials: a call for action!Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: an ex vivo experiment in human serous ovarian carcinoma.Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: analysis from the GCIG CALYPSO relapsing ovarian cancer trial.A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial.Quality indicators in ovarian cancer surgery: report from the French Society of Gynecologic Oncology (Societe Francaise d'Oncologie Gynecologique, SFOG).How to improve the prevention of chemotherapy-induced nausea and vomiting? The French NAVI study.Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer-The GCIG Symptom Benefit Study.Absorption and efficacy of acetylsalicylic acid in patients with short bowel syndrome.Quality of life in long-term cervical cancer survivors: a population-based study.
P50
Q28082909-347B14E5-4459-47D5-ADE1-EB931246075BQ30239092-56205562-D978-4029-B88D-8FC51BED318EQ30945359-B106CA24-1E5C-48DC-91D7-F1D5EDBAC85AQ33403609-3CC0E11F-9F5F-41F4-9EB7-D67F3729228FQ33419283-DD654FF8-1746-40C0-8BD9-432F3C81CE43Q34600979-767A4CE9-7C43-4C2A-AF92-0B81F3C2333AQ36287626-834D43A1-1BA8-4314-A7E8-D0AA543D202FQ36480044-800A1366-8E77-43BF-A6D9-C5E637FFD757Q36925044-60AE5283-2370-4B0B-AC40-C0CA9D0971BDQ37427275-CE9ECE79-A02E-436E-82E0-DA6DF8679296Q37476606-4BD1A7F6-244E-42C3-AE8A-3A7C9DA1059DQ37529822-611A76D9-A81C-44BE-B395-2F02260653E1Q37712562-25AFCC19-D7C6-4130-9F8E-DC782E858206Q38103770-038C2848-ACA7-4319-A923-05A4983B765CQ38203078-77188FEB-C98E-40E5-B63F-3CA9622E13B3Q38262154-2313154F-EEE7-40AD-8EAA-329F2CA2DEB7Q38347190-EB51A12F-7430-4665-B1E4-C8F3EE798189Q38582020-7094CE8C-7280-405D-BD17-38C5AC2F8D1CQ38690212-C73A60E9-A585-4124-90E3-8BAC8E8E1951Q38736653-38CAB71B-F3B0-4FE2-B547-6E47F5BAD453Q38922196-7CCF0025-FF93-4F7D-BE66-CEA4DDA20C5CQ39021494-877411F0-B572-4ECD-B1BF-EE045B55137FQ39043743-9276E9DA-20DB-45FC-815D-05169CC68208Q39544939-8B9560A2-1594-463F-AABF-1126664B9CDDQ40094748-1795904F-493D-457E-9C58-A48968E3592AQ40425397-49FE4689-57EB-44FA-AAAD-88D3BECF8E57Q41438678-96CE254F-52B0-40FE-84E7-65232AF7AE74Q41658924-5F01E6C4-F69A-4917-868E-6622CEA5039DQ42083096-12D77A1C-64D3-4345-9575-E0CB74E20774Q42142585-2055FC39-04E0-436D-87EE-5C04EDE2388DQ42689733-D6558E51-EEE6-461F-AB54-CFD76CE3D9DFQ42704678-F271DD0F-3D5A-4FB8-871F-49F1087924DCQ44114886-395C26AB-3FAA-42AC-8DF9-CEFB577BEDA7Q44131214-E43F5A4B-7751-4798-9B23-5D1BE1549F8AQ44296616-26042392-9730-4D64-91EF-87300B1964C8Q45385477-9227C784-5322-4316-91E3-EC93D12D9E11Q46106401-D9C66A1F-144E-479A-9CF4-9671E6EDD634Q46121510-02E4BAAC-4F48-486A-AC8C-8CBFA890E908Q46480960-5E3BA432-907A-4B6A-97BD-BD76E5674F45Q46516006-1E21BE83-5286-4CFD-847D-84F981E47700
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
研究者
@zh
name
Florence Joly
@ast
Florence Joly
@en
Florence Joly
@es
Florence Joly
@nl
type
label
Florence Joly
@ast
Florence Joly
@en
Florence Joly
@es
Florence Joly
@nl
prefLabel
Florence Joly
@ast
Florence Joly
@en
Florence Joly
@es
Florence Joly
@nl
P106
P31
P496
0000-0001-6168-4942